Staff turmoil continues at Focus Surgery, the Milpitas, CA, developerof high-frequency ultrasound ablation products. The firm announcedlate last month that CFO John Kehoe has stepped down. His dutieswill be assumed temporarily by vice president of
Staff turmoil continues at Focus Surgery, the Milpitas, CA, developerof high-frequency ultrasound ablation products. The firm announcedlate last month that CFO John Kehoe has stepped down. His dutieswill be assumed temporarily by vice president of planning PaulSullivan.
Kehoe's departure came several weeks after Focus cut its workforce by 40% (SCAN 9/27/95). Focus has posted a string of losingquarters as it moves to commercialize its Sonablate 200 productfor treatment of benign prostatic hyperplasia. The company saidlast month that it "continues to examine all financing alternatives,"but declined to be more specific about what those alternativesmight be.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.